{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In ovarian and lung cancers, LINC01342 acts as an oncogenic long non‐coding RNA that promotes tumor progression through its function as a competing endogenous RNA. In ovarian cancer, LINC01342 is upregulated and predominantly located in the cytoplasm, where it binds and sequesters microRNA‐30c‐2-3p. This “sponging” effect relieves the repression of HIF3A, thereby enhancing cell proliferation, migration, and clonality and correlating with poorer patient prognosis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Similarly, in lung cancer, increased LINC01342 expression contributes to tumor progression by binding to microRNA‐508-5p. This interaction leads to elevated levels of CRISP3, which in turn promotes cell proliferation, migration, invasion, and tumor growth, again associating high LINC01342 levels with adverse clinical outcomes."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Notably, while another long non‐coding RNA in the LINC family (LINC01355) has been identified as a tumor suppressor in breast cancer—where its downregulation facilitates cell cycle progression via a FOXO3/CCND1 axis"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "—LINC01342 displays contrasting oncogenic activity in other cancer types. Together, these findings underscore the diverse roles of LINC family lncRNAs in cancer, with LINC01342 facilitating tumor growth and metastasis through microRNA sponge mechanisms that deregulate key downstream targets.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Chu Zhang, Jie Liu, Yang Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Physiol (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcp.29289"}], "href": "https://doi.org/10.1002/jcp.29289"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31595977"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31595977"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Qiming Shen, Zhe Xu, Guanghao Sun, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC01342 silencing upregulates microRNA-508-5p to inhibit progression of lung cancer by reducing cysteine-rich secretory protein 3."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Death Discov (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41420-021-00613-x"}], "href": "https://doi.org/10.1038/s41420-021-00613-x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34504061"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34504061"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Bolun Ai, Xiangyi Kong, Xiangyu Wang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cell Death Dis (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41419-019-1741-8"}], "href": "https://doi.org/10.1038/s41419-019-1741-8"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31243265"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31243265"}]}]}]}